Spots Global Cancer Trial Database for Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Official Title: A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies
Study ID: NCT03680560
Study Description
Brief Summary: This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yale Smilow Cancer Hospital, New Haven, Connecticut, United States
Miami University Cancer Center, Miami, Florida, United States
The Ohio State University, Columbus, Ohio, United States
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Baylor Scott & White Medical Center, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Glen Weiss, MD
Affiliation: Cogent Biosciences, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
